Axon Stock Slumps on Dilution Fears After $1 Billion Notes Plan
Axon plans $1 billion of 0% convertible notes due 2031, plus a $150 million option.
Already have an account? Sign in.
Axon plans $1 billion of 0% convertible notes due 2031, plus a $150 million option.
Senators failed to reach 60 votes on the Clarity Act. All Democrats and four Republicans stopped debate on digital asset rules.
Ascendis will develop TransCon obesity and cardiometabolic programs itself after ending its Novo collaboration and starting a $400M buyback.
FDA cleared a grant-dependent myeloma IND for GTB-5550. Cheap preferred, 100% warrants, and a tiny float explain the selloff.